- Research article
- Open Access
- Open Peer Review
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA)
BMC Medical Genetics volume 15, Article number: 140 (2014)
Recent genome-wide association studies have identified multiple loci that are associated with an increased risk of developing coronary artery disease (CAD). The impact of these loci on the disease severity and prognosis of ischemic heart failure due to CAD is currently unknown.
We undertook association analysis of 7 single nucleotide polymorphism (rs599839, rs17465637, rs2972147, rs6922269, rs1333049, rs501120, and rs17228212) at 7 well established CAD risk loci (1p13.3, 1q41, 2q36.3, 6q25.1, 9p21.3, 10q11.21, and 15q22.33, respectively) in 3,320 subjects diagnosed with systolic heart failure of ischemic aetiology and participating in the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) trial. The primary outcome was the composite of time to first event of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, secondary outcomes included mortality and hospitalization due to worsening heart failure.
None of the 7 loci were significantly associated with the primary composite endpoint of the CORONA trial (death from cardiovascular cases, nonfatal myocardial infarction, and nonfatal stroke). However, the 1p13.3 locus (rs599839) showed evidence for association with all-cause mortality (after adjustment for covariates; HR 0.74, 95%CI [0.61 to 0.90]; P = 0.0025) and we confirmed the 1p13.3 locus (rs599839) to be associated with lipid parameters (total cholesterol (P = 1.1x10−4), low-density lipoprotein levels (P = 3.5 × 10−7) and apolipoprotein B (P = 2.2 × 10−10)).
Genetic variants strongly associated with CAD risk are not associated with the severity and outcome of ischemic heart failure. The observed association of the 1p13.3 locus with all-cause mortality requires confirmation in further studies.
Heart Failure (HF) is a highly prevalent condition affecting more than 15 million patients in Europe alone and has a poor prognosis . In several familial forms of HF, disease-causing mutations have been identified including several mutations in genes coding for structural components of the sarcomere ,. For example, mutations in the genes encoding cardiac β-myosin heavy chain (MYH7) or cardiac myosin-binding protein C (MYBPC3) are known to cause hypertrophic and dilated cardiomyopathies . However, these Mendelian diseases only account for a small minority of all HF cases and only explain a minor proportion of the population attributable risk for HF. The vast majority of HF is a consequence of more complex genetic and environmental factors and the interactions among them. Coronary artery disease (CAD) is considered the major cause of HF. For the development of CAD, a number of genetic risk loci with common variants have recently been identified -. The earliest findings derived from genome wide association studies were reported by the Wellcome Trust Case Control Consortium (WTCCC) and the German MI Family GWA studies, as well as the Coronary Artery Disease consortium, which together have identified 7 common variants that were robustly associated with CAD ,.
Whether these variants, with strong prior evidence to be associated with increased CAD risk, are also relevant for ischemic HF progression as reflected by HF severity and prognosis remains to be determined. In the present study, we have evaluated these 7 CAD risk loci in ischemic HF patients participating in the COntrolled ROsuvastatin multiNAtional study in heart failure (CORONA) and tested the hypothesis that the SNPs associated with CAD are also associated with ischemic HF disease severity and outcome.
The current study is a genetic sub-study of the CORONA trial. The CORONA trial aimed to determine the effect of rosuvastatin treatment on clinical outcome in patients with systolic heart failure from ischemic aetiology. The CORONA study group is represented in the supplement. The CORONA trial has been published in detail, the main result was that rosuvastatin did not reduce the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke ,.
In- and exclusion criteria of the CORONA trial have been reported in detail previously ,. In brief, patients were 60 years of age or older, HF of ischemic aetiology, and a left ventricular ejection fraction (LVEF) of ≤ 40% with NYHA class III/IV symptoms or LVEF ≤ 35% with NYHA class II symptoms. Patients had to be clinically stable and on optimal treatment for at least 2 weeks before inclusion. Exclusion criteria included the following; recent myocardial infarction (MI) (<6 months); unstable angina or stroke within the past 3 months; percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG); the implantation of a cardioverter defibrillator (ICD) or biventricular pacemaker within the past 3 months; heart transplantation; clinically significant/uncorrected primary valvular heart disease; hypertrophic cardiomyopathy; or systemic disease (e.g., amyloidosis). The CORONA trial included 5,011 patients , and DNA was obtained from 3,340 of them. We excluded 20 non-Caucasian subjects (8 black, 7 Asian, 5 ‘other’), leaving 3,320 subjects for the current genetic sub-study of CORONA. The ethical committee at each of the participating hospitals approved this trial (see Additional file 1), and patients provided written informed consent.
Definition of phenotypes and outcome
The severity of HF was assessed by LVEF and serum N-terminal pro B-type Natriuretic Peptide (NT-proBNP) levels. As one of the loci has also been identified in a GWAS for lipid traits, we specifically studied the association of this locus with available lipid traits. The primary outcome of the CORONA trial was the composite of death from cardiovascular cases, nonfatal myocardial infarction, and nonfatal stroke, analysed according to the time to the first event. Secondary outcomes were death from any cause, any coronary event (defined as sudden death, fatal or nonfatal myocardial infarction, the performance of PCI or CABG, ventricular defibrillation by an ICD, resuscitation after cardiac arrest, or hospitalization for unstable angina), death from cardiovascular causes, sudden death, death from worsening heart failure, combination of mortality or worsening heart failure and athero-thrombotic endpoint.
SNP selection and genotyping
We studied 7 loci (1p13.3, 1q41, 2q36.3, 6q25.1, 9p21.3, 10q11.21, 15q22.33) which have been linked to CAD risk by previous GWAS ,. We genotyped the 7 lead SNPs within these loci; rs599839, rs17465637, rs2972147, rs6922269, rs1333049, rs501120, and rs17228212 (Additional file 2: Table S1). Genotyping was carried out with TaqMan (Applied Biosystems) using standard protocols and was performed at the laboratory of AstraZeneca Pharmaceuticals (JCF), Alderley Park, UK without knowledge of clinical data.
Normality of the data was determined by visual inspection. HsCRP and NT-proBNP were non-normally distributed and therefore log-transformed. Genotypes were coded additively as 0, 1 or 2 in terms of the number of minor alleles. The baseline variables were analysed in linear model with only genotype as predictor and if significant, the following covariates were added to the adjusted model: age, sex, ejection fraction, NYHA class, systolic blood pressure, heart rate, body mass index, history of myocardial infarction, angina pectoris, diabetes mellitus, hypertension, stroke, intermittent claudication, aortic aneurysm, percutaneous coronary intervention, coronary artery bypass graft surgery, atrial fibrillation, implanted pacemaker, implanted cardiac defibrillator, smoking status, serum creatinine, alanine aminotransferase, creatine kinase, thyroid-stimulating hormone, triglycerides, hsCRP and NT-proBNP, as explained in detail by Wedel et al. . HF outcome determinants were analysed using Cox regression of outcome versus number of minor alleles. Analyses were conducted unadjusted and after adjusted for the above mentioned co-variates. We considered a P-value <0.0071 for the primary endpoint statistically significant (Bonferroni adjustment of <0.05 for 7 independent loci) and as suggestive for all secondary endpoint analyses.
The baseline characteristics of the study population are presented in Table 1. The study population consisted of 3,320 HF patients with mean LVEF of 31% and a median NT-proBNP level of 151 pmol/L. There was a high prevalence of hypertension, diabetes mellitus, and chronic kidney disease in our population. Subjects were well treated for HF, with 87% using diuretics, 77% using beta-blockers, 92% using ACE inhibitors or AT1-receptor antagonist, and 91% were treated with an antiplatelet agent or anticoagulant. The mean follow-up time was 2.73 years, accumulating 9,062 patient-years of follow-up. At baseline, 1,986 patients (60%) had a history of MI, and 823 (25%) a history of CABG or PCI. Genotyping was successful in excess of 98% for all SNPs but one and the distributions of genotypes were consistent with the Hardy-Weinberg equilibrium as calculated using the chi-square test for deviation. Minor allele frequencies were similar in the current analyses compared to the discovery GWAS ,. Details on genotyping can be found in Additional file 2: Table S1.
CAD loci and HF disease severity; LVEF and NT-proBNP
LVEF and NT-proBNP were taken as indicators of HF disease severity and their association with the 7 genetic loci was determined. Although some of the unadjusted association P-values were smaller than 0.05 (Table 2, Additional file 3: Table S2, and Additional file 4: Table S3), we considered none of these loci associated with LVEF or NT-proBNP considering the multiple testing burden of these secondary endpoints.
Prognostic value of CAD loci for cardiovascular events and disease progression in HF
Next, we tested the association between the CAD-associated loci with HF disease outcome. None of the 7 loci predicted the occurrence of the primary endpoint (composite endpoint of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke, analysed as time to first event) or death caused by cardiovascular events. When the individual components of the primary endpoint were considered, we observed that the 1p13.3 (rs599839) locus, showed a borderline association with all-cause mortality (HR 0.86, 95% CI [0.74-1.00], P = 0.499) which became somewhat stronger after adjustment for covariates (HR 0.74, [0.61-0.90], P = 0.0025). Using ordered Jonckheere-Terpstra test, the 1p13.3 locus also showed association with the total number of hospitalizations due to cardiovascular causes (P = 0.0093) and the 10q11.21 locus showed an association with the number of hospitalizations due to worsening HF. All associations with P < 0.05 are presented in Table 3 (all associations are presented in Additional file 5: Table S4 and Additional file 6: Table S5.
Associations of CAD loci with lipid profile in HF
The 7 loci were evaluated for association with the available serum lipid profile parameters. After adjustments, the 1p13.3 locus (rs599839) was associated with total cholesterol (P = 1.1 × 10−4), low-density-lipoprotein (LDL) cholesterol (P = 3.5 × 10−7), serum Apolipoprotein-B (Apo-B) levels (P = 5.1 × 10−8) and the Apo-B/Apo-A1 ratio (P = 8.0 × 10−9). Associations with lipid parameters with P-values smaller than 0.05 are presented in Table 4 (all associations are presented in Additional file 7: Table S6.
HF is a common condition in which cardiac function is affected, leading to a variety of symptoms like dyspnoea, fatigue, and fluid retention. The most frequent cause of HF is CAD. In the past few years, several genetic variants have been associated with CAD resulting in new insight in the pathophysiology of CAD . We tested the hypothesis that the presence of variants associated with prevalent CAD is also linked to increased severity of HF and worse prognosis. Our findings lend little support to this hypothesis. This was a candidate variant analyses and some of the observed associations are suggestive and require further replication.
The loci we evaluated included the 9p21 locus, which is considered the most robust common genetic risk factor for CAD with the rs1333049 variant showing the strongest signal for association with CAD in WTCCC and German studies . This locus harbours a large non-coding transcript of unknown function, designated the name CDKN2B antisense RNA (CDKN2BAS or ANRIL). This locus is related to atherosclerotic disease burden in different vascular beds  and deletion of ANRIL in human aortic smooth muscle cells leads to a increase in proliferative capacity in culture . Furthermore, the rate of proliferation of vascular smooth muscle cells is attenuated by the 9p21 genotype and the CAD risk allele (C allele) increases vascular smooth muscle cell proliferation, thereby likely playing an important role in the development of atherosclerosis . Despite these findings, the presence of this genetic variant, and presumably increased atherosclerotic burden, did not translate into increased HF severity or worse outcome in patients with ischemic HF in the present study. A possible explanation is that the effect of this locus acting through increased atherosclerotic disease burden is confounded by events defined by the severity of heart failure. In addition, the vulnerability to develop HF given a similar atherosclerotic disease burden might also differ among patients and could be a consequence of complex gene-environment interactions. The presence or absence of concomitant conditions and diseases including diabetes, renal dysfunction, or pulmonary disease may also modify the phenotype. Furthermore, patients in our study were well treated with beta-blockers, angiotensin-converting-enzyme inhibitors, and aldosterone antagonists, which might further have decreased the differences between patients due to genetic risk factors. Also related to optimisation of pharmacotherapy, Wedel et al. calculated specifically for the CORONA trial, that the proportionate contribution of myocardial infarction to total mortality, related to the atherosclerotic disease burden, was relatively small. The Wald statistic of myocardial infarction for total mortality was 3.9, while for example log NT-proBNP showed a Wald statistic for total mortality of 167 . This suggests that the pathological role of genetic risk variants acting through CAD might also be relatively small, and could therefore have remained undetected in our study. Nevertheless, the current sample size of systematically collected ischemic HF patients with DNA available to perform genotyping studies is the largest available in the world to date and it will be difficult, if not impossible, to extend the sample size within reasonable timeframes. The results of this study concurs with the lack of effect on CAD with rosuvastatin .
Considering prior knowledge, we also studied the association of the genotyped genetic variants with lipid parameters -. We were able to confirm previous reported associations between the 1p13.3 locus (rs599839) and lipids. We also provided novel data on this locus and its association with apolipoproteins. The 1p13.3 locus was most strongly associated with Apo-B levels (stronger than the known LDL association), suggesting Apo-B is a candidate effector molecule. The genomic region at 1p13.3 encodes 4 genes: proline/serine-rich coiled protein 1 (PSRC1), cadherin EGF LAG sevenpass G-type receptor 2 (CELSR2), myosin-binding protein H-like (MYBHL), and sortilin 1 (SORT1). Recent studies have revealed a role for SORT1 in Apo-B secretion and LDL catabolism: overexpression of SORT1 resulted in increased serum LDL and loss-of-function mutations were associated with protection against hypercholesterolemia and atherosclerosis ,. In our secondary analyses we observed an association with all-cause mortality and the number of hospitalizations due to cardiovascular causes for the 1p13.3 locus. As these were secondary analyses, which would not survive strict adjustment for multiple testing, the interpretation of these findings should be cautious as they require further confirmation. In addition, the explanation and possible relation to lower cholesterol and apolipoprotein levels cannot be deducted from the current study.
Among the strengths of the present study are the size and quality of the study cohort, which is the largest heart failure cohorts with DNA available to date. Patient characteristics and outcomes have been collected and documented systematically within the framework of a clinical trial. However, there are some limitations which we need to address. At first, we have limited the variants tested to the N.J. Samani paper published in 2007  and the variants reported by the Coronary Artery Disease Consortium in 2009 . Recent GWA studies have identified additional variants involved in CAD development. The recent publication by the CARDIoGRAMplusC4D consortium reported 46 genetic variants associated with CAD risk . We cannot exclude that there might be variants among these 46 that are related to heart failure outcomes and this remains an objective for further study. We performed a post-hoc power calculation to consider the possibility that our study might have lacked power . Assuming an effect size of the risk variant comparable to the CAD discovery GWAS (genotype relative risk Aa = 1.3; genotype relative risk AA = 1.6) ,, we calculated the power to detect a significant effect for a variant (prevalence cases = 0.175; number of cases = 581; control:case ratio = 4.7). The power of our analyses ranged from 0.90 to 0.91 depending on the frequency of the risk allele (ranging from 0.25 to 0.55). Future studies with larger sample sizes, containing all CAD loci, are warranted to further evaluate the influence of CAD genetic loci in heart failure.
Genetic variants associated with CAD and atherosclerotic disease burden are not associated with the severity and prognosis of patients with ischemic HF in the CORONA trial. The observed secondary association of the 1p13.3 locus with all-cause mortality requires confirmation in further studies.
Coronary artery disease
Controlled Rosuvastatin multinational study in heart failure
Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ: 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the European heart rhythm association. Eur J Heart Fail. 2010, 12 (11): 1143-1153. 10.1093/eurjhf/hfq192. Committee for Practice Guidelines of the European Society of Cardiolog ESC Committee for Practice Guidelines (CPG)
Morita H, Seidman J, Seidman CE: Genetic causes of human heart failure. J Clin Invest. 2005, 115 (3): 518-526. 10.1172/JCI24351.
Judge DP: Use of genetics in the clinical evaluation of cardiomyopathy. JAMA. 2009, 302 (22): 2471-2476. 10.1001/jama.2009.1787.
Waldmuller S, Erdmann J, Binner P, Gelbrich G, Pankuweit S, Geier C, Timmermann B, Haremza J, Perrot A, Scheer S, Wachter R, Schulze-Waltrup N, Dermintzoglou A, Schonberger J, Zeh W, Jurmann B, Brodherr T, Borgel J, Farr M, Milting H, Blankenfeldt W, Reinhardt R, Ozcelik C, Osterziel KJ, Loeffler M, Maisch B, Regitz-Zagrosek V, Schunkert H, Scheffold T, German Competence Network Heart Failure: Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German competence network heart failure. Eur J Heart Fail. 2011, 13 (11): 1185-1192. 10.1093/eurjhf/hfr074.
Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, et al: Genomewide association analysis of coronary artery disease. N Engl J Med. 2007, 357 (5): 443-453. 10.1056/NEJMoa072366.
Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, et al: Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011, 43 (4): 333-338. 10.1038/ng.784.
Samani NJ, Deloukas P, Erdmann J, Hengstenberg C, Kuulasmaa K, McGinnis R, Schunkert H, Soranzo N, Thompson J, Tiret L, Ziegler A, Coronary Artery Disease Consortium: Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol. 2009, 29 (5): 774-780. 10.1161/ATVBAHA.108.181388.
Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J, CORONA Study Group: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005, 7 (6): 1059-1069. 10.1016/j.ejheart.2005.09.005.
Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007, 357 (22): 2248-2261. 10.1056/NEJMoa0706201.
Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F, CORONA Study Group: Predictors of fatal and non-fatal outcomes in the controlled Rosuvastatin multinational trial in heart failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009, 11 (3): 281-291. 10.1093/eurjhf/hfn046.
Tragante V, Doevendans PA, Nathoe HM, van der Graaf Y, Spiering W, Algra A, de Borst GJ, de Bakker PI, Asselbergs FW, on behalf of the SMART study group: The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk. Eur Heart J. 2013, 34 (37): 2896-2904. 10.1093/eurheartj/eht222.
Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA: Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010, 464 (7287): 409-412. 10.1038/nature08801.
Motterle A, Pu X, Wood H, Xiao Q, Gor S, Ng FL, Chan K, Cross F, Shohreh B, Poston RN, Tucker AT, Caulfield MJ, Ye S: Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet. 2012, 21 (18): 4021-4029. 10.1093/hmg/dds224.
Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, Song K, Yuan X, Johnson T, Ashford S, Inouye M, Luben R, Sims M, Hadley D, McArdle W, Barter P, Kesaniemi YA, Mahley RW, McPherson R, Grundy SM, Bingham SA, Khaw KT, Loos RJ, Waeber G, Barroso I, Strachan DP, Deloukas P, Vollenweider P, Wareham NJ, Mooser V, Wellcome Trust Case Control Consortium: LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008, 371 (9611): 483-491. 10.1016/S0140-6736(08)60208-1.
Samani NJ, Braund PS, Erdmann J, Gotz A, Tomaszewski M, Linsel-Nitschke P, Hajat C, Mangino M, Hengstenberg C, Stark K, Ziegler A, Caulfield M, Burton PR, Schunkert H, Tobin MD: The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterol. J Mol Med (Berl). 2008, 86 (11): 1233-1241. 10.1007/s00109-008-0387-2.
Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, et al: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009, 41 (1): 56-65. 10.1038/ng.291.
Kjolby M, Andersen OM, Breiderhoff T, Fjorback AW, Pedersen KM, Madsen P, Jansen P, Heeren J, Willnow TE, Nykjaer A: Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010, 12 (3): 213-223. 10.1016/j.cmet.2010.08.006.
Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, Li X, Kumaravel A, Wang MY, Ai D, Guo L, Alexander ET, Nguyen D, Lund-Katz S, Phillips MC, Morales CR, Tall AR, Kathiresan S, Fisher EA, Musunuru K, Rader DJ: Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012, 122 (8): 2807-2816. 10.1172/JCI63563.
Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrups K, Konig IR, Cazier JB, Johansson A, Hall AS, Lee JY, Willer CJ, Chambers JC, Esko T, Folkersen L, Goel A, Grundberg E, Havulinna AS, Ho WK, Hopewell JC, Eriksson N, Kleber ME, Kristiansson K, Lundmark P, CARDIoGRAMplusC4D Consortium, et al: Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013, 45 (1): 25-33. 10.1038/ng.2480.
Purcell S, Cherny SS, Sham PC: Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003, 19 (1): 149-150. 10.1093/bioinformatics/19.1.149.
We acknowledge M. J. McLoughlin for the genotyping. Ethically approved collection and banking of biomaterials and genotyping was funded by AstraZeneca. The present analyses were supported by grant 95103007 from ZonMw and the Innovational Research Incentives Scheme (NWO VENI, Grant Number 916.76.170 to PvdH) of the Netherlands Organization for Health Research and Development, The Hague, the Netherlands.
This study was supported by AstraZeneca, Mölndal, Sweden. Dr. van Veldhuisen is an established investigator of the Netherlands Heart Foundation, Den Haag, Netherlands (Grant 2006 T037). N. Verweij is supported by the Netherlands Heart Foundation (grant NHS2010B280).
The authors declare that they have no competing interests.
JK HW JW DJvV were involved in the design and execution of the CORONA trial. All authors (VGH NV JK JCF HW JW WHvG RAdB DJvV PvdH) were involved in designing and setting up the current genetic experiment within the framework of the CORONA trial. All authors (VGH NV JK JCF HW JW WHvG RAdB DJvV PvdH) interpreted the analyses. VGH and PvdH prepared a first draft of the manuscript, which was improved further by incorporation of comments provided by all other authors (NV JK JCF HW JW WHvG RAdB DJvV). All authors read and approved the final manuscript.
Electronic supplementary material
About this article
Cite this article
Haver, V.G., Verweij, N., Kjekshus, J. et al. The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA). BMC Med Genet 15, 140 (2014) doi:10.1186/s12881-014-0140-3
- Coronary artery disease
- Heart failure
- Healthy ageing